313 related articles for article (PubMed ID: 24879173)
1. Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with Peg interferon alfa-2a and ribavirin.
Ennaifer R; Cheikh M; Romdhane H; Hefaiedh R; Ben Nejma H; Bel Hadj N
Tunis Med; 2014 Jan; 92(1):42-3. PubMed ID: 24879173
[No Abstract] [Full Text] [Related]
2. Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin.
Cauli C; Serra G; Chessa L; Balestrieri C; Scioscia R; Lai ME; Farci P
Haematologica; 2006 Jun; 91(6 Suppl):ECR26. PubMed ID: 16785129
[TBL] [Abstract][Full Text] [Related]
3. [Autoimmune hemolytic anemia in a case of chronic hepatitis type C 56 weeks after initiation of second line treatment with pegylated interferon alpha2b/ribavirin combination therapy].
Nishino R; Ikeda N; Unoura M
Nihon Shokakibyo Gakkai Zasshi; 2011 Sep; 108(9):1571-8. PubMed ID: 21891998
[TBL] [Abstract][Full Text] [Related]
4. [Side effects of interferon-based therapy for chronic hepatitis C virus infection and clinical management of them].
Iwasaki Y; Ikeda F; Yamamoto K
Nihon Rinsho; 2011 May; 69 Suppl 4():215-20. PubMed ID: 22096922
[No Abstract] [Full Text] [Related]
5. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV.
Slim J; Afridi MS
Infect Dis Clin North Am; 2012 Dec; 26(4):917-29. PubMed ID: 23083824
[TBL] [Abstract][Full Text] [Related]
6. Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit.
Gentile I; Viola C; Reynaud L; Borrelli F; Cerini R; Ciampi R; Piazza M; Borgia G
J Interferon Cytokine Res; 2005 May; 25(5):283-5. PubMed ID: 15871666
[TBL] [Abstract][Full Text] [Related]
7. [Development of sarcoidosis during treatment for chronic hepatitis C with pegylated interferon alfa-2a and ribavirin: case report and literature review].
Cacopardo B; Pinzone MR; Nunnari G
Infez Med; 2013 Mar; 21(1):40-44. PubMed ID: 23524900
[TBL] [Abstract][Full Text] [Related]
8. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
Ann Intern Med; 2013 Dec; 159(11):I-14. PubMed ID: 24297207
[No Abstract] [Full Text] [Related]
9. Severe autoimmune hemolytic anemia complicated with liver decompensation and invasive aspergillosis in a patient with chronic hepatitis C during treatment with peg-interferon-a and ribavirin.
Sykia A; Gigi E; Sinakos E; Bibashi E; Bellou A; Raptopoulou-Gigi M
J Gastrointestin Liver Dis; 2009 Mar; 18(1):118-9. PubMed ID: 19337648
[No Abstract] [Full Text] [Related]
10. A case of irreversible leukoencephalopathy in a patient with C virus hepatitis treated with pegylated interferon-alpha-2b and ribavirin.
Iacob SA; Petrescu AM; Iacob DG
Rom J Intern Med; 2013; 51(3-4):197-200. PubMed ID: 24620633
[TBL] [Abstract][Full Text] [Related]
11. Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients.
Lee SS; Roberts SK; Berak H; Dusheiko GM; Harley HA; Gane EJ; Husa P; Horsmans YJ; Hadziyannis SJ; Jenny Heathcote E; Messinger D; Tatsch F; Han KH; Ferenci P
Liver Int; 2012 Sep; 32(8):1270-7. PubMed ID: 22621707
[TBL] [Abstract][Full Text] [Related]
12. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.
Foster GR; Zeuzem S; Pianko S; Sarin SK; Piratvisuth T; Shah S; Andreone P; Sood A; Chuang WL; Lee CM; George J; Gould M; Flisiak R; Jacobson IM; Komolmit P; Thongsawat S; Tanwandee T; Rasenack J; Sola R; Messina I; Yin Y; Cammarata S; Feutren G; Brown KK
J Viral Hepat; 2013 Apr; 20(4):e115-23. PubMed ID: 23490379
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
[TBL] [Abstract][Full Text] [Related]
14. Retinal vein thrombosis associated with peginterferon alpha 2b plus ribavirin in a chronic hepatitis C patient.
Such Díaz A; Barrueco N; Esteban Alba C; Escobar Rodríguez I
Farm Hosp; 2011; 35(2):93-4. PubMed ID: 20615736
[No Abstract] [Full Text] [Related]
15. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
Gluhovschi C; Gadalean F; Kaycsa A; Curescu M; Sporea I; Gluhovschi G; Petrica L; Velciov S; Bozdog G; Bob F; Vernic C; Cioca D
Immunopharmacol Immunotoxicol; 2011 Dec; 33(4):744-50. PubMed ID: 21320001
[TBL] [Abstract][Full Text] [Related]
16. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
[TBL] [Abstract][Full Text] [Related]
17. Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction?
Simón-Talero M; Buti M; Esteban R
J Viral Hepat; 2012 Jan; 19 Suppl 1():14-7. PubMed ID: 22233409
[TBL] [Abstract][Full Text] [Related]
18. [Pegylated intereferon hematological safety in comparison with standard].
Fazylov VKh; Manapova ÉR; Tkacheva SV; Sozinova IuM
Eksp Klin Gastroenterol; 2012; (6):96-9. PubMed ID: 23402198
[TBL] [Abstract][Full Text] [Related]
19. [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
MMW Fortschr Med; 2002 Sep; 144(38):59. PubMed ID: 12395712
[No Abstract] [Full Text] [Related]
20. Unilateral hearing loss due to pegylated interferon-α2b and ribavirin therapy.
Jain S; Midha V; Sood A
Indian J Gastroenterol; 2011 Sep; 30(5):239-40. PubMed ID: 21986854
[No Abstract] [Full Text] [Related]
[Next] [New Search]
